PT - JOURNAL ARTICLE AU - Gaetano Alfano AU - Silvia Giovanella AU - Francesco Fontana AU - Jovana Milic AU - Giulia Ligabue AU - Francesco Giaroni AU - Camilla Ferri AU - Martina Montali AU - Andrea Melluso AU - Morisi Niccolò AU - Giacomo Mori AU - Riccardo Magistroni AU - Erica Franceschini AU - Andrea Bedini AU - Giacomo Cuomo AU - Margherita DiGaetano AU - Marianna Meschiari AU - Cristina Mussini AU - Gianni Cappelli AU - Giovanni Guaraldi TI - Similar Rates of AKI during the First Two Waves of COVID-19 in Northern Italy: a single-center study AID - 10.1101/2021.06.13.21258862 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.13.21258862 4099 - http://medrxiv.org/content/early/2021/06/17/2021.06.13.21258862.short 4100 - http://medrxiv.org/content/early/2021/06/17/2021.06.13.21258862.full AB - Introduction Two waves of COVID-19 cases have overwhelmed most European countries during 2020. It is unclear if the incidence of acute kidney injury (AKI) has changed during the COVID-19 outbreaks. This study aims to evaluate the differences in incidence, risk factors and outcome of AKI in patients with SARS-CoV-2 infection during the first and second wave of COVID-19.Method We reviewed the health medical records of 792 consecutive patients with COVID-19 hospitalized at the University Hospital of Modena, Italy, from February 25 to December 14, 2020.Results AKI was diagnosed in 122 (15.4%) patients. Incidence of AKI remained steady rate during wave-1 (15.9%) and wave-2 (14.7%) (P=0.89). AKI patients were older (P=<0.001) and had a more severe respiratory impairment (PO2/FO2) (P=≤0.001) than their non-AKI counterparts. AKI led to a longer hospital stay (P=0.001), complicated with a higher rate of ICU admission. COVID-19-related AKI was associate with 59.7% of deaths during wave-1 and 70.6% during wave-2. At the end of the period of observation, 24% (wave-1) and 46.7% (wave-2) of survivors were discharged with a not fully recovered kidney function. Risk factors for AKI in patients with COVID-19 were diuretics (HR=5.3; 95%CI, 1.2-23.3; P=0.025) and cardiovascular disease (HR, 2.23; 95%CI, 1.05-5.1; P=0.036).Conclusion The incidence of AKI (about 15%) remained unchanged during 2020, regardless of the trend of COVID-19. AKI occurred in patients with severe COVID-19 symptoms and was associated with a higher incidence of deaths than non-AKI patients. The risk factors of COVID-19-related AKI were diuretic therapy and cardiovascular disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNot fundedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the regional ethical committee of Emilia Romagna (n. 0013376/20)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable reques